NOVO-B.CO
$249.15
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Recent News
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
Each of these companies could benefit from this high-growth market over time.
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move
These companies are benefiting from a tidal wave of demand for new weight-loss drugs.
Health Care Roundup: Market Talk
1515 ET – For obesity-drug makers, success will be defined by price rather than product differentiation, HSBC analysts say. Pricing competition is set to heat up between Eli Lilly and Novo Nordisk, the analysts say. Lilly’s current guidance — which is more optimistic than Novo Nordisk’s — implies it will get a surge in GLP-1 demand when it cuts prices.
HSBC Downgrades Eli Lilly, Cuts PT to $850, Flags Obesity Market Risks
Analysts say pricing pressure and competition could limit market growth to $80B--$120B, below consensus expectations above $150B.
Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
Novo Nordisk (CPSE:NOVO B) has entered a partnership with Hims & Hers to provide access to its FDA approved GLP-1 obesity and diabetes drugs, Ozempic and Wegovy, through telehealth channels. The agreement resolves a public legal dispute between the two companies and could influence how patients in the United States access branded GLP-1 treatments. The announcement comes at a time of increasing competition and the rise of copycat medications in the obesity treatment space. For investors...